In the four years since AiCuris GMBH & Co. KG spun out of Bayer HealthCare's anti-infectives unit, it has continued to advance its inherited pipeline of antibacterial and antiviral drugs. AiCuris also has in-house research programs and is open to in-licensing for selected indications. Since nearly all of its drugs stem from novel chemical classes and target new modes of action, AiCuris describes its candidates as "resistance breaking by design."
Also see "AiCuris GMBH & Co. KG" - Scrip, 1 November, 2010.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?